Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 3/20 | 0.46 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.44 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL631929 | 0.96 | HSD17B10 (0.45) | HSD17B10TYRESR1ESR2HSD17B3 | |
| SCHEMBL875816 | 0.88 | TYR (0.61) | HSD17B10TYRESR1ESR2CA12 | |
| SCHEMBL2222155 | 0.85 | ALOX5 (0.64) | HSD17B10TYRESR1MAPTMEN1 | |
| SCHEMBL28361071 | 0.85 | ALOX5 (0.64) | HSD17B10TYRESR1MAPTMEN1 | |
| SCHEMBL9565680 | 0.83 | TYR (0.50) | HSD17B10TYRESR1ESR2HSD17B3 | |
| SCHEMBL365736 | 0.83 | HSD17B10 (0.52) | HSD17B10TYRESR1ESR2HSD17B3 | |
| SCHEMBL10825810 | 0.80 | TYR (0.55) | TYRESR1ESR2HSD17B3MAPT | |
| SCHEMBL31613067 | 0.80 | TYR (0.55) | TYRESR1ESR2HSD17B3MAPT | |
| SCHEMBL7494873 | 0.79 | HSD17B10 (0.48) | HSD17B10TYRESR1ESR2CA12 | |
| SCHEMBL28770665 | 0.79 | HSD17B10 (0.48) | HSD17B10TYRESR1ESR2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025059373-A1 | NOVEL PHENALKYLAMINES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-11266648-B2 | Substituted chromeno[2,3-d]pyrimidines as NF-κB inhibitors | ImmuneTarget, Inc. (US) | 2022-03-08 | — | — | US | disclosed |
| US-11083729-B2 | Methods of treating cancer with small molecule NF-κB inhibitors | ImmuneTarget, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200345739-A1 | SMALL MOLECULE NF-kB INHIBITORS | ImmuneTarget, Inc. | 2020-11-05 | — | — | US | disclosed |
| CN-111417396-A | Methods of treating cancer with small molecule NF-kB inhibitors | 免疫目标公司 | 2020-07-14 | — | — | CN | disclosed |
| US-10660894-B2 | Small molecule NF-κB inhibitors | ImmuneTarget, Inc. (US) | 2020-05-26 | — | — | US | disclosed |
| EP-3645007-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE NF-KB INHIBITORS | Immunetarget, Inc. (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20190142836-A1 | SMALL MOLECULE NF-kB INHIBITORS | ImmuneTarget, Inc. | 2019-05-16 | — | — | US | disclosed |
| US-10226464-B2 | Small molecule NF-κB inhibitors | ImmuneTarget, Inc. (US) | 2019-03-12 | — | — | US | disclosed |
| CN-109153683-A | 2H- chromene as NF- kB inhibitor simultaneously [2,3-D] pyrimidine -2,4 (3H)-diketone | 免疫目标公司 | 2019-01-04 | — | — | CN | disclosed |
| WO-2019006002-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE NF-KB INHIBITORS | IMMUNE TARGET, INC. (US) | 2019-01-03 | — | — | WO | disclosed |
| US-20190000851-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE NF-kB INHIBITORS | ImmuneTarget, Inc. | 2019-01-03 | — | — | US | disclosed |
| EP-3397641-A1 | 2H-CHROMENO[2,3-D]PYRIMIDINE-2,4(3H)-DIONES AS NF-KB INHIBITORS | Immunetarget, Inc. (US) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017117355-A1 | 2H-CHROMENO[2,3-D]PYRIMIDINE-2,4(3H)-DIONES AS NF-KB INHIBITORS | ImmuneTarget, Inc. (US) | 2017-07-06 | — | — | WO | disclosed |
| US-20170182051-A1 | SMALL MOLECULE NF-kB INHIBITORS | IMMUNETARGET INC (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142836-A1 | SMALL MOLECULE NF-kB INHIBITORS | NFKBIA, NFKB2, IKBKB | HSD17B10 2165/4885TYR 4313/4885ESR1 2379/4885 |
| US-11083729-B2 | Methods of treating cancer with small molecule NF-κB inhibitors | NFKBIA, IKBKB, RELA | HSD17B10 2906/4885TYR 4507/4885ESR1 2322/4885 |
| US-10660894-B2 | Small molecule NF-κB inhibitors | NFKBIA, RELA, NFKB2 | HSD17B10 2598/4885TYR 4650/4885ESR1 1794/4885 |
| US-10226464-B2 | Small molecule NF-κB inhibitors | NFKBIA, RELA, NFKB2 | HSD17B10 2598/4885TYR 4650/4885ESR1 1794/4885 |
| US-20170182051-A1 | SMALL MOLECULE NF-kB INHIBITORS | NFKBIA, NFKB2, IKBKB | HSD17B10 2165/4885TYR 4313/4885ESR1 2379/4885 |
| US-20190000851-A1 | METHODS OF TREATING CANCER WITH SMALL MOLECULE NF-kB INHIBITORS | NFKBIA, IKBKB, NFKB2 | HSD17B10 2353/4885TYR 4354/4885ESR1 2734/4885 |
| US-20200345739-A1 | SMALL MOLECULE NF-kB INHIBITORS | NFKBIA, NFKB2, IKBKB | HSD17B10 2165/4885TYR 4313/4885ESR1 2379/4885 |
| US-11266648-B2 | Substituted chromeno[2,3-d]pyrimidines as NF-κB inhibitors | NFKBIA, IKBKB, RELA | HSD17B10 2558/4885TYR 2145/4885ESR1 1021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.